- Home
- ELVA vs STTK Comparison
ELVA vs STTK Comparison
Compare ELVA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- STTK
- Stock Information
- Founded
- ELVA 1996
- STTK 2016
- Country
- ELVA Canada
- STTK United States
- Employees
- ELVA N/A
- STTK N/A
- Industry
- ELVA
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ELVA
- STTK Health Care
- Exchange
- ELVA Nasdaq
- STTK Nasdaq
- Market Cap
- ELVA 125.5M
- STTK 119.0M
- IPO Year
- ELVA N/A
- STTK 2020
- Fundamental
- Price
- ELVA $4.69
- STTK $2.14
- Analyst Decision
- ELVA Strong Buy
- STTK Hold
- Analyst Count
- ELVA 3
- STTK 5
- Target Price
- ELVA $6.50
- STTK $3.00
- AVG Volume (30 Days)
- ELVA 711.6K
- STTK 114.0K
- Earning Date
- ELVA 12-10-2025
- STTK 11-06-2025
- Dividend Yield
- ELVA N/A
- STTK N/A
- EPS Growth
- ELVA 58.59
- STTK N/A
- EPS
- ELVA 0.03
- STTK N/A
- Revenue
- ELVA $54,875,000.00
- STTK $1,000,000.00
- Revenue This Year
- ELVA $46.40
- STTK N/A
- Revenue Next Year
- ELVA $46.08
- STTK N/A
- P/E Ratio
- ELVA $171.66
- STTK N/A
- Revenue Growth
- ELVA 10.88
- STTK N/A
- 52 Week Low
- ELVA $1.80
- STTK $0.69
- 52 Week High
- ELVA $7.72
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- ELVA 37.55
- STTK 58.43
- Support Level
- ELVA $4.10
- STTK $1.93
- Resistance Level
- ELVA $4.78
- STTK $2.22
- Average True Range (ATR)
- ELVA 0.30
- STTK 0.17
- MACD
- ELVA -0.03
- STTK 0.02
- Stochastic Oscillator
- ELVA 37.50
- STTK 86.02
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.